Aptamer-modified Magnetic Nanosensitizer for in vivo MR imaging of HER2-expressing Cancer

The aim of this study was the development of a human epidermal growth factor receptor 2 (HER2)-targetable contrast agent for magnetic resonance imaging (MRI) with a high magnetic sensitivity. An anti-HER2 aptamer-modified magnetic nanosensitizer (AptHER2-MNS) was prepared by conjugation with 5′-thiol-modified aptamers and maleimidylated magnetic nanocrystals (MNCs). The physicochemical characteristics and targeting ability of AptHER2-MNS were confirmed, and the binding affinity (Kd) onto HER2 protein of AptHER2-MNS was 0.57 ± 0.26 nM. In vivo MRI contrast enhancement ability was also verified at HER2+ cancer cell (NIH3T6.7)-xenograft mouse models (n = 3) at 3T clinical MRI instrument. The control experiment was carried out using non-labeled MNCs. The results indicated that up to 150% contrast enhancement was achieved at the tumor region in the T2-weighted MR images after the injection of the AptHER2-MNS agent in mice that received the NIH3T6.7 cells. Electronic supplementary material The online version of this article (10.1186/s11671-018-2682-3) contains supplementary material, which is available to authorized users.


Background
Human epidermal growth factor receptor 2 (HER2), which belongs to the epidermal growth factor receptor (EGFR) family, plays a key role in human malignancies and is overexpressed in approximately 30% of human breast cancers [1] and in many other cancer types, including stomach, bladder, ovarian, and lung carcinomas [1][2][3][4]. Patients with HER2overexpressing breast cancer tend to have substantially lower survival rates than patients with non-overexpressing HER2 cancers [5]. In addition, the overexpression of HER2 leads to increased breast cancer metastasis [6][7][8]. For this reason, HER2 serves as an important biomarker in the diagnosis of cancer. In the clinical setting, HER2 is used as a typical biological marker, along with the estrogen receptor (ER) and progesterone receptor (PR), to diagnose the breast cancer. Thus, breast cancer patients receive a definite diagnosis following histological verification of HER2, ER, and PR expression levels. However, histological verification is invasive and is only carried out in a limited number of lesions. For this reason, various research has been conducted to visualize the diagnostic markers non-invasively via radiological examination before histological verification based on computed tomography [9,10], positron emission tomography [11][12][13], single-photon emission computed tomography [14][15][16], magnetic resonance imaging (MRI) [17][18][19][20], and multimodal imaging tools [21][22][23].
Iron oxide nanoparticles (IONPs) are used in various non-invasive radiological examinations for the observation of clinically relevant biomarkers [24,25]. IONPs are compatible with molecular imaging because they have a higher magnetic sensitivity or biocompatibility than other heavy metal-based MRI contrast agents such as gadoliniumbased contrast agents (GBCAs) or nickel-or cobalt-containing contrast agents. In particular, although commercialized MRI contrast agents and GBCAs are associated with problems related to in vivo toxicity due to the release of Gd 3+ ions, the IONP-based MRI contrast agents have higher in vivo safety than GBCAs because they can be degraded to iron, absorbed, or eliminated [26,27].
To apply IONPs for molecular imaging, the targeting moieties are extremely important and can be chemicals, carbohydrates, proteins, antibodies, or aptamers [25,28,29]. Among these molecules, aptamers have stable three-dimensional structure of a single-strand nucleic acid which has high binding affinity and specificity on specific molecules. Aptamers' high binding affinity is caused by their developing technique and systematic evolution of ligands by exponential enrichment (SELEX) [30]. SELEX is using very large libraries of random sequence oligonucleotides (~10 15 ) can be provided by chemical synthesis and screened in parallel to find aptamers which have high binding affinity on target molecule. As a result of SELEX, aptamers could be developed with high binding affinity of picomolar concentration-level generally while that of other biomolecules is ranging from micromole to subnanomole [31,32]. In the case of the recently developed third-generation aptamers, they also have in vitro and in vivo stability due to their improved resistance against DNase or RNase by using modified nucleic acids [33,34]. For these reasons, aptamers are emerging as the preferred moieties in molecular imaging research [35].
The objective of this study was the development of an aptamer-modified T2 contrast agent based on magnetic nanocrystals (MNCs) with a high specificity to cancer cells overexpressing HER2. To achieve this objective, MNCs, which have high magnetic sensitivity, were prepared by a thermal decomposition method and a HER2-specific aptamer (K d = 0.42 nM) was used. The synthesized contrast agents were characterized by analyzing the morphology, magnetization property, and magnetic relaxivity. As well, we carried out in vitro and in vivo targeting assays against HER2 proteins in a tumor xenograft animal model implanted with a HER2-expressing cancer cell line, respectively.

Synthesis of MNCs
The monodisperse magnetic iron oxide nanoparticles were synthesized using Sun's thermal decomposition method [36]. These magnetic nanoparticles are called MNCs due to their iron(III) acetylacetonate and oleic acid precursors. Briefly, a mixture of iron(III) acetylacetonate (2 mmol), oleic acid (6 mmol), 1-octadecene (6 mmol), 1,2-hexadecanediol (10 mmol), and benzyl ether (20 mL) was loaded in a three-necked round bottom flask and stirred mechanically. To remove residual oxygen molecules and water, the mixture was preheated to 100°C for 30 min. The preheated mixture was then heated to 200°C for 2 h and refluxed at 300°C for 30 min under a flow of nitrogen. After the reactants were cooled to room temperature by removing the heat source, the reactants were purified with excess ethyl alcohol. Centrifugation was performed in triplicate to separate the product from any undispersed residue. The Fe 3 O 4 nanoparticle products were then redispersed in 5 mL hexane. The final product was synthesized by repeating the procedure described above with 100 mg Fe 3 O 4 and its precursors. The MNC morphologies were evaluated using a high-resolution transmission electron microscope (HR-TEM, JEM-2100, JEOL Ltd., Japan). The saturation of magnetization was evaluated using a vibrating sample magnetometer (VSM, MODEL-7300, Lakeshore, USA) at room temperature. The quantity of MNCs in the product was analyzed by measuring the weight using a thermo-gravimetric analyzer (SDT-Q600, TA Instrument), and the MNCs were washed until the content of Fe 3 O 4 reached approximately 80%.

Synthesis of Maleimidyl-TWEEN ® 80
For the preparation of maleimidyl T80 (Tm80), 15.3 mmol MPA and 22.9 mmol N,N′-dicyclohexylcarbodiimide were dissolved in 10 mL dichloromethane, respectively, and subsequently mixed. The mixture was then added to 20 mL dichloromethane containing 7.6 mmol T80, followed by the addition of 3.2 mL triethylamine into the mixture. Finally, 22.9 mmol 4-(dimethylamino) pyridine was dissolved in 10 mL dichloromethane, and all of the reagents were mixed in a 70 mL vial. The final mixture was stirred using a magnet for 48 h. The color of the mixture changed from apricot to a red wine color. After reacting for 48 h, the crystalized urea was removed by filtration. To eliminate the dichloromethane, the reaction was filtered by evaporation in a rotary evaporator (N-1100, EYELA, Japan). The resulting product was suspended in deionized water, and the unconjugated reagents were removed by dialysis (Spectra/Por®, 1 kDa MWCO, Spectrum Laboratory Inc., USA). The final product was prepared by freeze-drying. The synthesized Tm80 was confirmed by comparison with MPA and T80 using a UV-vis spectrometer (UV-1800, Shimadzu, Japan), Fourier-transform infrared (FT-IR) spectrometer (Perki-nElmer, spectrum two), and 1 H-nuclear magnetic resonance (NMR) spectrometer (Bruker Biospin, Advance II, see Additional file 1: Figure S1).

Preparation of Maleimidyl MNCs
Water-dispersable maleimidyl MNCs (mWMNCs) were prepared using the nanoemulsion method [37]. Briefly, 100 mg Tm80 was fully disolved in 20 mL deionized water, and 4 mL n-hexane containing 20 mg MNCs was rapidly injected in ther Tm80-disolved water with ultrasonication (190 W) and stirring (1200 rpm). The emulsion process continued for 10 min with ice-cooled bath. The remained organic solvent was evaporated for 12 h at room temperature, and the products were purified by dialysis (Spectra/Por®, 3.5 kDa MWCO, Spectrum Laboratory Inc., USA) to remove excess surfactant for 3 days. The mWMNCs were then concentrated using a centrifugal filter (NMWL 3000, Amicon® Ultra, Merk Milipore Ltd., Germany) to 1.25 mg Fe /mL in DEPCtreated water. The T80-enveloped MNCs (WMNCs) were also prepared using the same method.

Preparation of Apt HER2 -MNS
Before conjugation between mWMNCs and anti-HER2 aptamers, the reduction step of thiol-modified aptamers was carried out. Briefly, 1 nmol aptamer was dissolved in 0.3 mL deionized water, and triethylamine acetate and 1,4-dithiltretol solution were added by which the final concentration was 50 and 25 mM, respectively. This mixture was shaked at room temperature for 1.5 h, and it was purified and desalted by ethanol precipitation. To prepare the Apt HER2 -MNS, HER2-specific MRI probe, molecular weight of MNCs was calculated theoretically (see Additional file 1: Figure S2) and the mix ratio of mWMNCs and aptamer was designated as 1:7. Therefore, 100 μg (Fe) mWMNCs (as Fe 3 O 4 , 45 pmol) was dissolved in PBS (1 mL) and 5 μg (0.35 nmol) aptamer was added. The mixture was stirred at room temperature for 5 min and incubated at 4°C for 2 h. The distribution of the hydrodynamic diameter of the Apt HER2 -MNS was then analyzed using a dynamic laser scattering analyzer (ELS-Z, Otsuka Electronics, Japan). To confirm the ability of the Apt HER2 -MNS as an MRI contrast agent, T2 relaxivity (R2) analysis was performed with a 1.5 T clinical MRI instrument with a micro-47 surface coil (Intera, Philips Medical System, Netherlands) using various concentrated phantoms of Apt HER2 -MNS. The R2 of the Apt HER2 -MNS was measured using the Carr-Purcell-Meiboom-Gill (CPMG) sequence at room temperature: TR = 10 s, 32 echoes with 12 ms even echo space, number of acquisitions = 1, point resolution = 156 μm × 156 μm, and section thickness = 0.6 mm. The R2 was defined as 1/T2 with s −1 units.

Apt HER2 -MNS Binding Affinity Assay
For the validation of the HER2-specificity of Apt HER2 -MNS, the nitrocellulose filter-binding method was used [38]. The naked Apt HER2 and Apt HER2 -MNS were dephosphorylated using alkaline phosphatase (New England Biolabs, MA, USA). The 5′ or 3′ end of the aptamers was labeled by T4 polynucleotide kinase and [ 32 P]-ATP (Amersham Pharmacia Biotech, NJ, USA) [39]. The binding assays were conducted by incubating the 32 P-labeled aptamers at a concentration of 10 pM with the HER2 protein at concentrations ranging from 100 to 10 pM in selection buffer (20 mM Tris·HCl, pH 7.5 at 4°C, 6 mM NaCl, 5 mM 2-mercaptoethanol, 1 mM Na 3 EDTA, 10% v/v glycerol) at 37°C for 30 min. The mixture of the 32 P-labeled aptamers and the HER2-protein was filtered by G-50 column (GE Heathcare Life Science, UK) to remove free radioisotopes. The filtered mixtures were developed on the reusable film, and fractions of the HER2 protein-bound aptamers were quantified using a phosphorimager (Fuji FLA-5100 Image Analyzer, Tokyo, Japan). To eliminate the effect of the nonspecific background binding of the radiolabeled aptamer to the nitrocellulose filter, the raw binding data was corrected by conducting the experiment using 32 P-labeled aptamers only.

In Vivo MRI
All animal experiments were conducted under the approval of the Association for Assessment and Accreditation of Laboratory Animal Care International. The in vivo MRI scans were conducted using a syngeneic mouse tumor model, which was generated by the implantation of NIH3T6.7 cells (1.0 × 10 7 cells) into the thighs of 5-week-old female BALB/c nude mice. After 2 weeks, the tumor size was evaluated by MRI. When the tumor size reached approximately 500 mm 3 , 100 μg (5 mg/kg) Apt HER2 -MNS was injected into the tail vein. In vivo MRI experiments were performed using a 3.0 T clinical MRI instrument and an 8-channel human wrist coil. For T2-weighted MRI at 3.0 T, the following parameters were adopted: TR/TE = 1054/70 ms, number of acquisitions = 2, point resolution = 400 × 319 mm, and slice thickness = 1 mm TSE factor = 8. The contol experiments were carried out using WMNCs with the same method. All T2 signal intensities were calculated by averaging approximately five regions of interest (ROIs) drawn on the T2-weighted MRI images of each mouse model (n = 3), and R2 (or R2*) value, inversed value of T2, was used in the signal intensity analysis. The changes over time of relative signal intensity were normalized by initial signal intensity (pre-injection). The histogram analysis was also conducted on the R2 signal intensity of voxel in ROI.

Histological Analysis
Prussian blue staining, can be used to detect Fe ion in tumor tissues, was conducted to confirm the Apt HER2 -MNS targeting of HER2-expressing cancer following the harvesting of tumor tissue from each tumor model after the in vivo MRI. The harvested tumor tissues were fixed in 10% formalin solution for 24 h and embedded in paraffin after dehydration in increasing ethanol concentrations and clarification in Histo-Clear® (National Diagnotics, USA). Prussian blue staining was conducted by mounting the tissue slices (thickness = 5 μm) onto glass slides followed by deparaffination and hydration using Histo-Clear® and concentrated ethanols, respectively. After that, the slides were placed in the Prussian blue working solution (10% potassium ferrocyanide and 20% hydrochloric acid solution = 1:1) for 1 h. The nuclei were stained using Nuclear Fast Red stain (Sigma Aldrich, USA). After washing the tissue samples three times for 30 min, we added 2-3 drops of the mounting solution onto the slides and then covered the slides with cover slips. The stained tissue sections were observed using a Olympus BX51 and Olyvia software (Olympus, Japan).

Results and Discussion
Apt HER2 -MNS was designed as a single-moleculetargeting agent based on IONPs for the molecular imaging of HER2-expressing tumors using MRI. Hence, Apt HER2 -MNS needed to have a high specificity for the target molecule and a large magnetic susceptibility. To obtain a high magnetic sensitivity firstly, the MNCs, monodisperse Fe 3 O 4 nanoparticles, were synthesized using the thermal decomposition and seed growth method [36]. Experimental procedure of preparation and in vivo application of Apt HER2 -MNS was described in Fig. 1. Firstly, the size and shape of the MNCs were confirmed by HR-TEM (Fig. 2a, b). In Fig. 2c, the average size of MNCs was measured by the random selection of 130 MNCs from the TEM image, and a very narrow size distribution (10.49 ± 1.74 nm) and spherical shape were observed. The superparamagnetic property of the MNCs was also evaluated by VSM, which yielded a MNC saturation magnetization value of 98.8 emu/g Fe (Fig. 2d). The T2 contrast agent, which was currently available by intravenous injection, was based on superparamagnetic iron oxides (SPIO) or ultrasmall superparamagnetic iron oxides (USPIO) [40]. SPIO or USPIO also have superparamagnetic properties, but they have a saturation magnetization value less than 70 emu/g Fe [40][41][42][43]. The superparamagnetic property is necessary for using IONPs as an intravenous contrast agent because it causes IONPs to have a magnetic property only when they were in the magnetic field, and it prevents IONPs from aggregating. Furthermore, higher saturation magnetization value of MNCs could be helpful to reducing injection dose than SPIO or USPIO-based contrast agents.
In order to use MNCs for in vivo experiments, WMNCs and mWMNCs were prepared by a nanoemulsion method using T80 or Tm80, respectively. The physicochemical characteristics of prepared Tm80 and its precursors, MPA and T80, were confirmed by absorbance, FT-IR, 1 H-NMR spectral analysis (see Additional file 1: Figure S1). As previously published [44], mWMNCs prepared by the nanoemulsion method using Tm80 is stably dispersed in water. Furthermore, the maleimidyl groups of mWMNCs can be easily conjugated with a molecule that has neutral pH thiol groups and this conjugation does not generate any side products. Furthermore, NapdU-modified aptamer was used to increase in vivo half-life, and its half-life was 151 h in human serum (see Additional file 1: Figure S3). Apt HER2 -MNS was prepared by conjugation between mWMNCs and Apt HER2 -SH, and the hydrodynamic properties of Apt HER2 -MNS were evaluated using dynamic laser scattering and MR relaxivity analysis (Fig. 3). The diameters of WMNCs and Apt HER2 -MNS were 28.8 ± 7.2 and 34.1 ± 8.2 nm, respectively (Fig. 3a). Because the Apt HER2 consisted of 40-mer oligonucleotides and was approximately 5-10 nm in length, the presence of Apt HER2 might cause the difference of hydrodynamic diameter. The relaxivity of WMNCs and Apt HER2 -MNS was 265.7 and 257.2 mM −1 Fe s −1 , respectively (Fig. 3b), which was evaluated to confirm their magnetic sensitivity as an MRI contrast agent. In the case of T2 contrast agents based on SPIO or USPIO, which are FDA approved, they were almost synthesized by the co-precipitation method. For this   Fe s −1 ) under the magnetic field [40]. By using MNCs in this study, Apt HER2 -MNS had 35~500%-increased magnetic relaxivity than SPIOor USPIO-based T2 contrast agents.
The binding affinity of Apt HER2 -MNS for HER2 protein was evaluated using a filter binding assay (Fig. 4a), and the resulting K d values of Apt HER2 -SH and Apt HER2 -MNS were measured as 26.88 ± 8.24 and 0.57 ± 0.26 nM, respectively (Fig. 4b, c). Apt HER2 -OH has a very high specificity for HER2 proteins with a K d value of 0.42 ± 0.05 nM, and this binding affinity is approximately 10-fold higher than 5 nM of Herceptin® [45]. However, the binding affinity of the naked Apt HER2 can be changed by conjugation with the chemicals, molecules, or nanoparticles. Therefore, the binding affinity of Apt HER2 for HER2 proteins should be evaluated after conjugation with mWMNCs. The binding affinity of Apt HER2 -SH for HER2 was reduced by the presence of a thiol-group rather than by the naked Apt HER2 because thiol group can be bound with other thiol residue in proteins or other thiol-modified aptamers. However, the binding affinity of Apt HER2 -MNS was measured as similar to that of Apt HER2 , this result means that neither there is no enough unbound Apt HER2 -SH which can interrupt the interaction between aptamer and HER2 protein nor mWMNCs have no or very few influences on the binding affinity of aptamers.
In vivo MRI experiments were performed using the syngeneic mouse tumor models to evaluate the ability of Apt HER2 -MNS to target HER2-overexpressing tumors. Using a tumor model that was generated by the implantation of NIH3T6.7 cells into the thigh, an MRI experiment was conducted from pre-injection to 120 min after the injection of WMNCs or Apt HER2 -MNS (Fig. 5, see also Additional file 1: Figure S4). T2 contrast enhancement effect by IONP-based contrast agents is observed as darken image because they induce T2 shortening effect of around protons. Therefore, in the signal intensity analyses, T2 or T2* values were represented by R2 or R2*. R2, an inversed value of T2, is used to compare the signal intensity with positive value. In the case of WMNCs, the highest R2 signal intensity was observed 30 min after injection of WMNCs after which it gradually decreased (Fig. 5a, b). At 120 min after the injection of WMNCs, the T2 signal intensity resembled the pre-injection state. The change rate in the average value of R2 signal intensity was less than 10%; thus, it was hard to recognize in the T2-weighted MR with the naked eye. In the previous study, it was demonstrated that the T80-enveloped iron oxide nanoparticles accumulated around the tumor tissues despite the absence of any targeting moieties [46]. However, in that study, a contrast agent dose of 1.4 mg Fe per mouse was used in the T2-weighted MRI, which was 14-fold higher than the dose used in this study. This means that WMNCs could not show effective contrast enhancement efficacy in the experiment at a dose of 0.1 mg Fe per mouse (5 mg Fe /kg). The time series change of R2* signal intensity was also less than 10%, and there was no statistical significance. In contrast, 120 min after injection, Apt HER2 -MNS caused a 130% higher signal intensity enhancement than before the injection of Apt HER2 -MNS despite using the same injection dose as WMNCs (Fig. 5c, d). This injection dose was 2-to 30-folds lower than that of other studies about aptamer-modified magnetic nanoparticle-based contrast agent [44,47,48]. This result indicated that Apt HER2 -MNS has a higher targeting ability than either WMNCs or other aptamer-modified contrast agent, and also suggested that the high contrast enhancement effect of Apt HER2 -MNS might be expected despite a lower dose than WMNCs. The contrast enhancement mainly appeared in the peripheral vessels and in the center of the tumor tissue. Although the peripheral Fig. 5 In vivo MR images of HER2+ tumor mouse model using WMNCs (n = 3) or Apt HER2 -MNS (n = 3). a T2-and T2*-weighted MR images at the pre-or post-injection of WMNCs. b Relative signal intensity graph measured from a. c T2-and T2*-weighted MR images at the pre-or postinjection of Apt HER2 -MNS. d Relative signal intensity graph and e the intensity histogram of tumor region measured from c. f Histological analysis data obtained after MR imaging. Error bars were represented by positive y-axis only. Relative signal intensities of b, d, and e were measured from the red solid-lined ROI of a, c, and Additional file 1: Figure S4 vessels were darkened soon after the injection of Apt HER2 -MNS, the contrast enhancement in the center of the tumor lesion first appeared at 60 min and tended to increase up to 120 min.
To emphasize the visible change in the contrast enhancement effects before and after the injection of Apt HER2 -MNS, a histogram analysis of the R2 signal intensity was conducted in the ROIs at the T2-weighted MRI images (Fig. 5e). Because the T2 signal is apparent as the negative enhancement in T2-weighted MRI images, it was represented by R2. After injection of Apt HER2 -MNS, the center of the histogram was shifted to the right side. The approximately 10% increase of contrast enhancement was observed when the difference of the center of histograms was calculated.
To confirm the presence of Apt HER2 -MNS in the tumor histologically, Prussian blue staining was conducted ( Fig. 5f ). In Prussian blue stained tissue, nucleus and cytoplasm were stained as deep or light pink color, and several blue colored dots were observed around tumor cells. We assumed that the tumor tissues stained blue in color if Apt HER2 -MNS targeted the tumor. In the results of the Prussian blue staining, the blue dots were observed in the tumor tissues, and the tissue slides of Apt HER2 -MNS had approximately 3-folds as much the number of blue dots as those of WMNCs. Prussian blue staining can detect the Fe ion in tissues; thus, it was used to confirm the accumulation of the contrast agent based on IONPs in the tumor tissues [44,49,50].

Conclusions
In conclusion, we confirmed that Apt HER2 -MNS works as an in vivo HER2-targetable MRI contrast agent by physicochemical characterization and in vivo MRI experiments in HER2-expressing mouse tumor models. Apt HER2 -MNS has a high relaxivity and specificity to HER2, and it demonstrated marked contrast enhancement effects despite a lower administration dose than other T2 contrast agents, due to the iron oxide nanoparticles. This contrast agent is expected to provide information regarding the expression of HER2 cancer in cancer patients and could be utilized to monitor HER2+ cancer patients during chemotherapy using HER2 target drugs. We expect that the results of this work will offer a promising strategy for the diagnosis of HER2-overexpressing cancer and for patient treatment.